Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company's stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15% of TG Therapeutics at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of TGTX. Danske Bank A S bought a new stake in shares of TG Therapeutics during the third quarter worth about $25,000. EverSource Wealth Advisors LLC lifted its position in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 365 shares in the last quarter. Hantz Financial Services Inc. lifted its position in TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 560 shares in the last quarter. Truvestments Capital LLC lifted its position in TG Therapeutics by 172.4% in the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 1,026 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in TG Therapeutics during the 4th quarter valued at about $52,000. Institutional investors own 58.58% of the company's stock.
TG Therapeutics Price Performance
TG Therapeutics stock opened at $54.27 on Friday. TG Therapeutics, Inc. has a 52 week low of $26.76 and a 52 week high of $59.30. The company's 50 day moving average price is $53.02 and its two-hundred day moving average price is $40.90. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23. The stock has a market cap of $8.31 billion, a P/E ratio of 19.81, a P/E/G ratio of 2.33 and a beta of 1.62.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. During the same period in the prior year, the company earned $0.17 earnings per share. The business's revenue was up 70.2% on a year-over-year basis. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Bank of America boosted their price objective on TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a report on Tuesday, July 7th. Jefferies Financial Group restated a "buy" rating and issued a $83.00 target price on shares of TG Therapeutics in a report on Monday, June 22nd. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $65.00 to $72.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Weiss Ratings reiterated a "hold (c+)" rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Finally, B. Riley Financial increased their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a "buy" rating in a research report on Monday, July 27th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $63.00.
Check Out Our Latest Stock Analysis on TGTX
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
